2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023

2019 ASCCP Risk-Based Management Consensus Guidelines Committee

Producción científica: Articlerevisión exhaustiva

10 Citas (Scopus)

Resumen

This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.

Idioma originalEnglish (US)
Páginas (desde-hasta)3-6
Número de páginas4
PublicaciónJournal of Lower Genital Tract Disease
Volumen28
N.º1
DOI
EstadoPublished - ene 1 2024

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Huella

Profundice en los temas de investigación de '2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023'. En conjunto forman una huella única.

Citar esto